Australian Clinical Labs Ltd (AU:ACL) has released an update.
Australian Clinical Labs Limited has announced an update on its ongoing share buy-back program, revealing the purchase of 7,143 ordinary fully paid shares on the previous day, adding to a total of 125,000 shares bought back to date. This move is part of the company’s on-market buy-back strategy, aiming to manage its capital and share value effectively.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.